BANDERA, ALESSANDRA
 Distribuzione geografica
Continente #
NA - Nord America 3.954
AS - Asia 2.504
EU - Europa 1.892
SA - Sud America 408
AF - Africa 53
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 5
Totale 8.823
Nazione #
US - Stati Uniti d'America 3.820
SG - Singapore 929
CN - Cina 610
RU - Federazione Russa 369
HK - Hong Kong 354
BR - Brasile 337
VN - Vietnam 336
DE - Germania 274
IT - Italia 265
IE - Irlanda 258
SE - Svezia 244
GB - Regno Unito 107
UA - Ucraina 105
CA - Canada 91
FI - Finlandia 57
DK - Danimarca 54
IN - India 51
AR - Argentina 36
ID - Indonesia 33
FR - Francia 32
ZA - Sudafrica 30
KR - Corea 29
TR - Turchia 29
BD - Bangladesh 24
NL - Olanda 24
AT - Austria 23
JP - Giappone 23
PL - Polonia 22
MX - Messico 21
IQ - Iraq 17
ES - Italia 15
BE - Belgio 13
IR - Iran 11
EC - Ecuador 9
SA - Arabia Saudita 8
CO - Colombia 6
HN - Honduras 6
LT - Lituania 6
MA - Marocco 6
AE - Emirati Arabi Uniti 5
EU - Europa 5
KE - Kenya 5
PK - Pakistan 5
UZ - Uzbekistan 5
AU - Australia 4
AZ - Azerbaigian 4
BZ - Belize 4
CL - Cile 4
CR - Costa Rica 4
CZ - Repubblica Ceca 4
EG - Egitto 4
JO - Giordania 4
NP - Nepal 4
PY - Paraguay 4
UY - Uruguay 4
CH - Svizzera 3
DO - Repubblica Dominicana 3
IL - Israele 3
MY - Malesia 3
PE - Perù 3
PT - Portogallo 3
TW - Taiwan 3
VE - Venezuela 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
BH - Bahrain 2
BO - Bolivia 2
KH - Cambogia 2
LB - Libano 2
LV - Lettonia 2
ML - Mali 2
MN - Mongolia 2
PH - Filippine 2
RO - Romania 2
SC - Seychelles 2
SI - Slovenia 2
TN - Tunisia 2
BB - Barbados 1
BG - Bulgaria 1
BS - Bahamas 1
BY - Bielorussia 1
EE - Estonia 1
GR - Grecia 1
JM - Giamaica 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MD - Moldavia 1
NG - Nigeria 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
OM - Oman 1
PR - Porto Rico 1
SN - Senegal 1
TH - Thailandia 1
Totale 8.823
Città #
Singapore 558
Ann Arbor 375
Ashburn 358
Hong Kong 351
Fairfield 276
Chandler 271
Dublin 253
Houston 190
Woodbridge 186
Wilmington 174
Frankfurt am Main 168
New York 149
Dallas 134
Ho Chi Minh City 111
Los Angeles 111
Seattle 102
Jacksonville 100
Beijing 96
Dearborn 96
Cambridge 94
Milan 84
Hanoi 83
Princeton 71
Santa Clara 67
Hefei 65
Shanghai 50
Buffalo 43
The Dalles 43
Nanjing 41
São Paulo 34
Lawrence 32
Altamura 31
Moscow 31
Ottawa 28
Munich 27
Helsinki 26
Chicago 24
Seoul 24
Tokyo 22
Fremont 21
Florence 20
Kent 20
Nanchang 20
San Diego 20
Jakarta 19
Lachine 19
Denver 18
Dong Ket 18
Nuremberg 17
Rio de Janeiro 17
Toronto 17
Hangzhou 16
London 16
Brussels 13
Guangzhou 13
Salt Lake City 13
San Jose 13
Andover 12
Brooklyn 12
Council Bluffs 12
Edmonton 12
Shenyang 12
Vienna 12
Warsaw 12
Amsterdam 11
Columbus 11
Redondo Beach 11
Brasília 10
Changsha 10
Durban 10
Hebei 10
Kunming 10
Orem 10
Quận Bình Thạnh 9
Boardman 8
Boston 8
Buenos Aires 8
Chennai 8
Da Nang 8
Ha Long 8
Johannesburg 8
Kiev 8
Montreal 8
Norwalk 8
Poplar 8
Pune 8
Tianjin 8
Falls Church 7
Jinan 7
San Francisco 7
Zhengzhou 7
Belo Horizonte 6
Elk Grove Village 6
Miami 6
Ninh Bình 6
Romola 6
Turku 6
Ankara 5
Atlanta 5
Baghdad 5
Totale 5.658
Nome #
Similar success rates but lower incidence of telaprevir-related rash in HIV/HCV coinfected as compared to HCV-monoinfected patients treated with triple anti-HCV therapy 307
Microbiota in ICU, not only a gut problem 305
Effects of autologous stem cell transplantation in HIV: searching for the origins of viral replication in settings of profound CD4(+) T cell depletion 287
Brief Report: Peripheral Monocyte/Macrophage Phenotypes Associated with the Evolution of Cognitive Performance in HIV-Infected Patients 277
A case of cerebrospinal fluid viral escape on a dual antiretroviral regimen: Worth the risk? 273
Impact of orotracheal intubation and mechanical ventilation on the microbiota of the lung in the development of Ventilator- Associated Pneumonia 273
Prospective immune dynamics during the first 24 weeks of efavirenz based-antiretroviral therapy in HIV-1-infected subjects, according to CD4+ T-cell counts at presentation: The IMMUNEF clinical trial 263
Brachial and central blood pressure in HIV-infected subjects 261
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART 258
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 257
Strategies to limit immune-activation in HIV patients 248
Evaluation of adhesion molecules and immune parameters in HIV-infected patients treated with an atazanavir/ritonavir- compared with a lopinavir/ritonavir-based regimen 235
ECMO: An alternative support for acute respiratory failure caused by tuberculosis? 233
A case of classic neuromyelitis optica (Devic's syndrome) triggered by pegylated-interferon α 232
Customization of LC-MS-based proteomic workflows for biological studies in the clinical field 228
Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: Results of the "cOPA" pilot randomized trial 219
Combination antifungal therapy for invasive mold infections among pediatric patients with hematological malignancies: Data from a real-life case-series 216
Unmasking tuberculosis in the era of antiretroviral treatment 214
Lung cryptococcosis in a treated HIV-1-infected patient with suppressed viral load and past disseminated cryptococcosis: Relapse or late IRIS? 213
KIR-HLA genotypes in HIV-infected patients lacking immunological recovery despite effective antiretroviral therapy 209
Use of CXCR4-antagonist for haematopoietic stem cell mobilization in HIV-infected patients with haematological malignancies 207
Changes in subcutaneous adipose tissue microRNA expression in HIV-infected patients 206
Plasma Proteomic Variables Related to COVID-19 Severity: An Untargeted nLC-MS/MS Investigation 205
Untargeted mass spectrometry approach to study SARS-CoV-2 proteins and characterize human plasma and saliva proteome in COVID-19 patients. 192
Impact of dexamethasone on the incidence of ventilator-associated pneumonia in mechanically ventilated COVID-19 patients: a propensity-matched cohort study 182
Characterization of immune failure by monocyte activation phenotypes in HIV-infected patients receiving antiretroviral therapy 180
Under representation of the inhibitory KIR3DL1 molecule and the KIR3DL1+/BW4+ complex in HIV exposed seronegative individuals 176
Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations 173
High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects Data from the ICONA Foundation Cohort 171
Plasma proteome investigation of COVID-19 patients with different outcomes through an untargeted label-free LC-MS/MS approach. 167
SARS-CoV-2 RNA in plasma samples of COVID-19 affected individuals: a cross-sectional proof-of-concept study 163
Exogenous reinfection of tuberculosis in a low-burden area 150
Predictors of COVID-19 Readmission Among Patients Previously Hospitalized for SARS-CoV-2 147
Early changes in adhesion molecules expression and endothelial function in patients initiating ART with Atazanavir or Lopinavir 147
HIV-DNA decrease during treatment in primary HIV-1 infection with three different drug regimens: Italian Network of Acute HIV Infection (INACTION) clinical trial 146
Plasma proteomic signatures related to COVID-19 disease severity by an untargeted nLC-ESI-MS/MS approach 143
Evaluation of HIV transmission clusters among natives and foreigners living in Italy 138
Unmasked tuberculosis or lymphoma in late AIDS presenters: A difficult differential diagnosis 136
Arterial structural and functional effects of two different antiretroviral therapy protocol on naïve HIV-infected subjects 135
Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study 130
Corrigendum: The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study(Front. Med., (2022), 9, (850858), 10.3389/fmed.2022.850858) 130
Characterization of SARS-CoV-2 proteins and human proteome in COVID-19 patients’ saliva and plasma: an untargeted mass spectrometry approach 127
Plasma, Intracellular and Lymph Node Antiretroviral Concentrations and HIV DNA Change During Primary HIV Infection: Results from the INACTION P25 Study 121
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 119
3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir 116
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 107
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 107
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 105
Occupational HIV infection in a research laboratory with unknown mode of transmission: a case report 3
Totale 9.237
Categoria #
all - tutte 32.963
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 32.963


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021239 0 0 0 0 0 0 40 55 47 37 21 39
2021/2022474 15 21 46 60 20 48 21 36 23 55 29 100
2022/2023959 102 316 74 113 40 129 10 68 65 8 23 11
2023/2024754 19 14 46 32 92 217 144 37 52 23 6 72
2024/20251.813 88 181 125 90 147 78 131 38 206 318 155 256
2025/20262.718 675 331 438 467 537 243 27 0 0 0 0 0
Totale 9.237